Why KYMR Stock surged +3.29% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, KYMR scores 50 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC -21.4%; FCF yield -2.3%), signaling that the business is not currently generating returns on invested capital or free cash flow relative to its value. Whale 13F Flow scores 17 of 20, reflecting institutional accumulation and options positioning, the strongest pillar in the set. Insider Conviction scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10 of 20 (Beta 0.95; sector sensitivity). Forensic Balance Sheet scores 13 of 20 (Altman Z 26; Piotroski F 4/9; Debt/Equity 0.04). For a prospective investor, the rating's central tension is that institutional positioning is supportive while the cash-generation and insider-conviction pillars are weak, and the verdict reflects the weaker side. Valuation (P/E TTM 32.7; Forward P/E 30.4) is being paid for earnings that the cash-flow and accrual data does not yet confirm, so the upside case depends on cash realization catching up with reported profit.

Kymera Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. The source data does not describe its products, customers, or revenue model. The profile identifies a market capitalization of $10.2B. Gross margin is reported as 0%, and the financials show revenue of $39.2M for FY 2025.

Per the SEC financials, revenue declined from $78.6M (FY 2023) to $47.1M (FY 2024) and $39.2M (FY 2025), while operating losses widened from $-165.5M to $-349.4M. Reported net income is positive in each period, but operating margin is -60% and net margin is 68%, and free cash flow is negative in all three years. ROIC is -21.4%. Per the Roarable RQD rating, the Altman Z-Score is 26, the Piotroski F-Score is 4 of 9, and Debt/Equity is 0.04. Cash rose to $357.0M in FY 2025 while debt was $73.4M.

Per the news wire, the six most recent items are all tagged to KYMR. Yahoo Finance's "Could You Have Seen The Run In Kymera Stock Coming?" and Seeking Alpha's "Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon" are rated YELLOW. A Yahoo Finance item references "KT 621" ahead of earnings, and a GuruFocus item covers the Q3 2026 earnings call. The marketscreener.com item, "Earnings Flash (KYMR) Kymera Therapeutics Posts Q3 Loss $1.32 a Share, vs. FactSet Est of $1.26 Loss," is rated RED under RISK WATCH, indicating a loss per share wider than the FactSet estimate. A Stocks Down Under item addresses whether the company can build blockbuster medicines. Per the Butterfly Supply-Chain Graph, the proprietary signal is an ACCOUNTING_MIRAGE, labeled ACCRUAL & WORKING CAPITAL WATCH, with severity 83 and direction BEARISH. The signal states that net income growth of +39.1% diverged from operating cash flow growth of -19.7%, with a +58.8% cash conversion gap and working-capital and receivables expansion of +48.5%.

• What are KYMR's products, pipeline stage, and revenue sources, given that the source data does not describe the business beyond its industry classification?
• What drove the positive net income of $311.4M in FY 2025 against operating losses of $-349.4M, and does the source data identify the non-operating items involved?
• Will operating cash flow turn positive, and when will the working-capital build reverse as the ACCRUAL & WORKING CAPITAL WATCH signal anticipates?
• What is the EV/EBITDA and cash runway, given that EV/EBITDA is unavailable and cash of $357.0M against FCF of $-234.3M is not translated into a runway figure?
• Do the 13F whale positions and options flow reflect the same view that the insider and cash pillars do not support?